Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have metastatic castration-resistant prostate cancer (prostate cancer that has spread and no longer responds to hormone-lowering treatment), confirmed by a laboratory test of tissue or cells showing a specific type called adenocarcinoma.
- People whose prostate cancer has continued to grow or spread while receiving treatment that lowers androgen (male hormone) levels.
- People who are generally well enough to carry out daily activities with little or no limitation (based on a standard medical fitness scale scored 0 or 1).
- People whose cancer progressed during hormone-lowering treatment and who have previously received at least one specific hormone-blocking medicine (called an androgen receptor pathway inhibitor) as well as one or two courses of a chemotherapy type known as taxane-based chemotherapy.
Who may not be able to join:
- People whose prostate cancer has been identified as a type other than adenocarcinoma, such as small cell or neuroendocrine carcinoma.
- People with serious heart problems or significantly reduced heart function.
- People with major health conditions, such as an infection that is not under control or seriously abnormal blood or laboratory test results.
- People who have previously been treated with a type of therapy known as an androgen receptor degrader.
- Other criteria set out in the study protocol may also apply (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: GSK Clinical Trials, GlaxoSmithKline
Phone: 877-379-3718
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with dose limiting toxicities (DLTs); Number of participants with adverse events (AEs), and serious adverse events (SAEs); Number of participants with adverse events (AEs), and serious adverse events (SAEs) by Severity; Number of participants with AEs leading to dose modifications
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.